Biosciences
Activities led by Venture Partners at CU Boulder, the university’s commercialization arm, generated an economic impact of $8 billion nationally and $5.2 billion in the state of Colorado over the last five years.
Breathalyzer based on frequency comb spectroscopy quantum tech shows promise as a non-invasive diagnostic test for an array of diseases.
When pregnant moms breathe dirty air, it may adversely impact their baby’s brain, CU Boulder research suggests.
CU Boulder’s International Genetically Engineered Machine team has developed a “magic soybean” that can churn out scarce pharmaceutical compounds while going easy on the environment.
Researchers building a budding life sciences startup leverage venture development programming to achieve a major funding milestone.
Cheaper, faster test trades uncomfortable nose swab for spit-in-a-tube simplicity in effort to detect virus before it spreads
With antibiotic-resistant “superbugs” infecting 2 million people per year, and a dearth of new medications in the pipeline to treat them, CU Boulder researchers are taking a novel approach to addressing the looming public health crisis.
New shelf-stable vaccines could bolster lifesaving immunization deliveries worldwide.
Mounting evidence shows healthy resident bacteria can play a pivotal role in supporting physical health.